Literature DB >> 25901678

Cancer: An essential passenger with p53.

James E Bradner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901678     DOI： 10.1038/nature14390

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  7 in total

1.  Cancer vulnerabilities unveiled by genomic loss.

Authors:  Deepak Nijhawan; Travis I Zack; Yin Ren; Matthew R Strickland; Rebecca Lamothe; Steven E Schumacher; Aviad Tsherniak; Henrike C Besche; Joseph Rosenbluh; Shyemaa Shehata; Glenn S Cowley; Barbara A Weir; Alfred L Goldberg; Jill P Mesirov; David E Root; Sangeeta N Bhatia; Rameen Beroukhim; William C Hahn
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

Review 2.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

3.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

4.  TP53 loss creates therapeutic vulnerability in colorectal cancer.

Authors:  Yunhua Liu; Xinna Zhang; Cecil Han; Guohui Wan; Xingxu Huang; Cristina Ivan; Dahai Jiang; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Pulivarthi H Rao; Dipen M Maru; Andreas Pahl; Xiaoming He; Anil K Sood; Lee M Ellis; Jan Anderl; Xiongbin Lu
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

5.  Passenger deletions generate therapeutic vulnerabilities in cancer.

Authors:  Florian L Muller; Simona Colla; Elisa Aquilanti; Veronica E Manzo; Giannicola Genovese; Jaclyn Lee; Daniel Eisenson; Rujuta Narurkar; Pingna Deng; Luigi Nezi; Michelle A Lee; Baoli Hu; Jian Hu; Ergun Sahin; Derrick Ong; Eliot Fletcher-Sananikone; Dennis Ho; Lawrence Kwong; Cameron Brennan; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

6.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

7.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962
  7 in total
  9 in total

1.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

2.  TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.

Authors:  Zhe Chen; Jiayi Guo; Kun Zhang; Yanxing Guo
Journal:  Dis Markers       Date:  2016-04-27       Impact factor: 3.434

3.  Synergistic cytotoxic effects of a combined treatment of a Pinellia pedatisecta lipid-soluble extract and cisplatin on human cervical carcinoma in vivo.

Authors:  Mingxing Zhang; Yi Yu; Hongwei Zhang; Haixia Huang; Qingqing Cai; Yu Kang; Guiling Li; Congjian Xu
Journal:  Oncol Lett       Date:  2017-04-25       Impact factor: 2.967

4.  Highly Selective 5-Formyluracil Labeling and Genome-wide Mapping Using (2-Benzimidazolyl)Acetonitrile Probe.

Authors:  Yafen Wang; Chaoxing Liu; Fan Wu; Xiong Zhang; Sheng Liu; Zonggui Chen; Weiwu Zeng; Wei Yang; Xiaolian Zhang; Yu Zhou; Xiaocheng Weng; Zhiguo Wu; Xiang Zhou
Journal:  iScience       Date:  2018-11-02

Review 5.  New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.

Authors:  Ye Han; Xiaopeng Yu; Shuqiang Li; Ye Tian; Caigang Liu
Journal:  Front Oncol       Date:  2020-11-25       Impact factor: 6.244

Review 6.  Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.

Authors:  Yingming Sun; Zhe Wang; Sufang Qiu; Ruoyu Wang
Journal:  Int J Biol Sci       Date:  2021-03-10       Impact factor: 6.580

7.  FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion.

Authors:  Yichao Fan; Jiao Yue; Mengtao Xiao; Han Han-Zhang; Yao Vickie Wang; Chun Ma; Zhilin Deng; Yingxiang Li; Yanyan Yu; Xinghao Wang; Shen Niu; Youjia Hua; Zhiping Weng; Peter Atadja; En Li; Bin Xiang
Journal:  Elife       Date:  2017-08-02       Impact factor: 8.140

8.  Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways.

Authors:  Lei Liu; Lin Pang; Yunfeng Wang; Ming Hu; Zhuo Shao; Diwei Huo; Denan Zhang; Hongbo Xie; Jingbo Yang; Qiuqi Liu; Xiujie Chen
Journal:  Oncotarget       Date:  2018-04-20

9.  HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport.

Authors:  Peihua Luo; Zhifei Xu; Guanqun Li; Hao Yan; Yi Zhu; Hong Zhu; Shenglin Ma; Bo Yang; Qiaojun He
Journal:  Autophagy       Date:  2018-09-11       Impact factor: 16.016
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.